[Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
Li
Yan
Y
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Weng
Dan-hui
DH
Kong
Fan-fei
FF
Fan
Liang-sheng
LS
Hu
Yi
Y
Song
Xiao-hong
XH
Xing
Hui
H
Wang
Wei
W
Ma
Ding
D
Wang
Shi-xuan
SX
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000378:metabolism; D053181:Caspase 8 / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D011719:Pyrazines / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001897:Boronic Acids; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; C506386:CFLAR protein, human; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; C505530:CASP8 protein, human; D053181:Caspase 8; D002945:Cisplatin